{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-033507","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.558684+00:00","generated_at":"2026-06-16T06:19:11.928948+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protara reports positive Phase 1a data for TARA-002 in NMIBC; plans Phase 2 trial in 2H2023","bullets":["TARA-002 well tolerated at all three doses; no dose-limiting toxicities; 40KE dose selected for further trials.","Of 3 evaluable CIS patients, 1 heavily pre-treated BCG-unresponsive patient achieved complete response; tumor regression in other 2.","ADVANCED-2 Phase 1b/2 trial to enroll up to 102 CIS patients (BCG-naïve and BCG-unresponsive) starting 2H2023.","Company expects current resources to fund operations into 2025, supporting clinical plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-033507","json":"https://secwatch.observer/filing/0001213900-23-033507.json","markdown":"https://secwatch.observer/filing/0001213900-23-033507.md","text":"https://secwatch.observer/filing/0001213900-23-033507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023033507/0001213900-23-033507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023033507/ea177564-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:19:11.928948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}